Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last days
Enjoy this offer
* See conditions under "Our services"

Valuation: Castle Biosciences, Inc.

Market Cap 627M 540M 497M 466M 876M 59.22B 885M 5.88B 2.3B 29B 2.35B 2.3B 100B P/E Ratio 2026 *
-14.9x
P/E Ratio 2027 * -22.2x
Enterprise Value 627M 540M 497M 466M 876M 59.22B 885M 5.88B 2.3B 29B 2.35B 2.3B 100B EV / Sales 2026 *
1.78x
EV / Sales 2027 * 1.59x
Free-Float
97.27%
Yield 2026 *
-
Yield 2027 * -
1 day+1.55%
1 week-0.43%
Current month-0.43%
1 month+8.64%
3 months-18.74%
6 months-46.25%
Current year-46.04%
1 week 20.38
Extreme 20.375
21.52
1 month 18.48
Extreme 18.48
22.18
Current year 17.72
Extreme 17.722
44.28
1 year 14.59
Extreme 14.59
44.28
3 years 12.07
Extreme 12.07
44.28
5 years 9.26
Extreme 9.2601
78.92
10 years 9.26
Extreme 9.2601
107.69
Manager TitleAgeSince
Chief Executive Officer 64 2007-08-31
Director of Finance/CFO 56 2017-11-30
Chief Tech/Sci/R&D Officer - 2021-11-30
Director TitleAgeSince
Director/Board Member 64 2007-08-31
Chairman 64 2014-08-31
Director/Board Member 70 2018-12-05
Date Insider Type Main position Quantity % Market Cap.
05-31Fiscal year

Founder

22,264 0.0734%
05-27Free

Chairman

11,766 0.0388%
05-27Free

Director

11,766 0.0388%
Change 5-day change 1-year change 3-year change Capi.($)
+1.55%-0.43%+8.93%+59.26% 627M
+1.68%+0.74%+165.88%+253.41% 17.21B
+0.96%-4.49%-43.63%-26.25% 9.23B
+0.22%+4.88%+34.75%+18.79% 6.81B
+0.33%+7.40% - - 5.14B
-1.12%-3.49%-28.64%-32.34% 5.07B
+5.84%+4.31%+96.02%+93.66% 4.14B
-1.28%-6.05%-29.30%-34.05% 4.14B
+1.91%+6.80%+196.73%-43.78% 4.09B
-1.87%+4.27%-15.94%-41.98% 2.71B
Average +0.82%+3.80%+42.75%+27.41% 5.92B
Weighted average by Cap. +0.98%+3.15%+66.40%+75.42%

Financials

2026 *2027 *
Net sales 352M 304M 280M 262M 493M 33.3B 498M 3.3B 1.29B 16.31B 1.32B 1.29B 56.44B 393M 339M 312M 292M 549M 37.13B 555M 3.68B 1.44B 18.18B 1.47B 1.44B 62.92B
Net income -43.06M -37.11M -34.16M -32.04M -60.19M -4.07B -60.79M -404M -158M -1.99B -162M -158M -6.9B -25.65M -22.11M -20.35M -19.09M -35.86M -2.42B -36.21M -241M -93.96M -1.19B -96.26M -94.22M -4.11B
Net Debt - -
Logo Castle Biosciences, Inc.
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers around six commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology ophthalmology and includes a test to guide systemic treatment decisions in patients with moderate-to-severe AD. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for patients with cutaneous squamous cell carcinoma (SCC).
Employees
942
Date Price Change Volume
26-06-16 21.00 $ +1.65% 70,637
26-06-15 20.66 $ -0.19% 220,462
26-06-12 20.70 $ -1.48% 154,629
26-06-11 21.01 $ -0.33% 215,218
26-06-10 21.08 $ 0.00% 245,606
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
20.66USD
Average target price
44.00USD
Spread / Average Target
+112.97%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CSTL Stock
- 40% : Our Best Subscriber-Only Tools to Spot Tomorrow’s Top Investments!
d
:
:
SEIZE THE OFFER!